Effect of bone marrow-derived mononuclear cells on nerve regeneration in the transection model of the rat sciatic nerve

Goel, Rohit; Suri, Vaishali; Suri, Ashish; Sarkar, Chitra; Mohanty, Sujata; Sharma, Meher Chand; Yadav, Pradeep Kumar; Srivastava, Arti

doi:10.1016/j.jocn.2009.01.031

Cited by 60 publications

(77 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, however, the positive effects of undifferentiated cells have also been widely reported [5,7,13,[32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51] . These investigators claim that in vitro differentiation incurs an unnecessary delay, limiting clinical applicability.…”

Section: Differentiationmentioning

confidence: 99%

Augmenting peripheral nerve regeneration using stem cells: A review of current opinion

Fairbairn

Meppelink

Ng-Glazier

et al. 2015

WJSC

128

View full text Add to dashboard Cite

Outcomes following peripheral nerve injury remain frustratingly poor. The reasons for this are multifactorial, although maintaining a growth permissive environment in the distal nerve stump following repair is arguably the most important. The optimal environment for axonal regeneration relies on the synthesis and release of many biochemical mediators that are temporally and spatially regulated with a high level of incompletely understood complexity. The Schwann cell (SC) has emerged as a key player in this process. Prolonged periods of distal nerve stump denervation, characteristic of large gaps and proximal injuries, have been associated with a reduction in SC number and ability to support regenerating axons. Cell based therapy offers a potential therapy for the improvement of outcomes following peripheral nerve reconstruction. Stem cells have the potential to increase the number of SCs and prolong their ability to support regeneration. They may also have the ability to rescue and replenish populations of chromatolytic and apoptotic neurons following axotomy. Finally, they can be used in non-physiologic ways to preserve injured tissues such as denervated muscle while neuronal ingrowth has not yet occurred. Aside from stem cell type, careful consideration must be given to differentiation status, how stem cells are supported following transplantation and how they will be delivered to the site of injury. It is the aim of this article to review current opinions on the strategies of stem cell based therapy for the augmentation of peripheral nerve regeneration.

show abstract

Section: Differentiationmentioning

confidence: 99%

Augmenting peripheral nerve regeneration using stem cells: A review of current opinion

Fairbairn

Meppelink

Ng-Glazier

et al. 2015

WJSC

128

View full text Add to dashboard Cite

show abstract

“…As bone marrow-derived mononuclear cells (MC) have already been successfully used as an experimental therapy in several organs and tissues, such as heart, liver, tendon, peripheral nervous system, and kidney [18,19,20,21,22,23,24], these cells might be an alternative to the existing prevention and treatment strategies for diabetic nephropathy. Thus, our aim was to investigate whether bone marrow-derived MCs might be used in the treatment of early stage diabetic nephropathy in rats.…”

Section: Introductionmentioning

confidence: 99%

Bone Marrow-Derived Mononuclear Cells Promote Improvement in Glomerular Function in Rats with Early Diabetic Nephropathy

Castiglione

Maron‐Gutierrez

Barbosa

et al. 2013

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Diabetic nephropathy is one of the main causes of end-stage renal disease. The present study investigated the effect of mononuclear cell (MC) therapy in rats subjected to diabetic nephropathy. Methods: Male Wistar rats were divided into control (CTRL), diabetic (DM), CTRL+MC and DM+MC groups. Diabetes was induced by a single injection of streptozotocin (45 mg/kg, i.p.) and, 4 weeks later, 2×10⁷ MCs were injected via the jugular vein. Results: The rats in the DM and DM+MC groups showed increased glycemia, glomerular filtration rate and glomerular tuff area versus control groups. The glomerular filtration rate and glomerular tuff area were normalized in the DM+MC group. No alterations were observed in the fractional excretion of electrolytes and proteinuria between the DM and DM+MC groups. TGF-β1 protein levels in the DM group were significantly increased versus control animals and normalized in the DM+MC group. An increase in ED1⁺/arginase I⁺ macrophages and IL-10 renal expression was observed in the DM+MC group versus DM group. Conclusions: Bone marrow-derived MC therapy was able to prevent glomerular alterations and TGF-β1 protein overexpression and modulated glomerular arginase I⁺ macrophage infiltration in rats subjected to early diabetic nephropathy.

show abstract

“…21,22 Two studies used marrow mononuclear cells. 7,14 These cells were used because they were easily obtained, they can differentiate into neural cells in an appropriate biological environment, and because remyelination has been previously demonstrated with intravenous administration with this cell type. 7 Franchi et al specifically selected neural stem cells to evaluate their use in the CCI model.…”

Section: Spinal Cord Injurymentioning

confidence: 99%

“…7,14 These cells were used because they were easily obtained, they can differentiate into neural cells in an appropriate biological environment, and because remyelination has been previously demonstrated with intravenous administration with this cell type. 7 Franchi et al specifically selected neural stem cells to evaluate their use in the CCI model. 6 Several properties of these cell types made them favorable to the authors, which included their role as direct precursors to neural cells, the role in maintaining nervous tissue, and in the collaboration with immune cells after nerve injury.…”

Section: Spinal Cord Injurymentioning

confidence: 99%

Potential role of stem cells for neuropathic pain disorders

Vadivelu

Willsey

Curry

et al. 2013

FOC

View full text Add to dashboard Cite

Chronic neuropathic pain is a debilitating disease process associated with several medical disorders. Different from pain caused by inflammation, neuropathic pain is a diffuse pain disorder often found to be recalcitrant to the limited medical treatments available. Intractable nerve pain may benefit from other therapies capable of longer-lasting pain coverage or greater efficacy. A growing number of reports have emerged suggesting a role for stem cells as a cellular delivery source with neuroprotective agents opposing the effects of nerve damage. Here, the authors review the current experimental therapies examining the use of stem cells for the treatment of neuropathic pain disorders.

show abstract

Effect of bone marrow-derived mononuclear cells on nerve regeneration in the transection model of the rat sciatic nerve

Cited by 60 publications

References 36 publications

Augmenting peripheral nerve regeneration using stem cells: A review of current opinion

Augmenting peripheral nerve regeneration using stem cells: A review of current opinion

Bone Marrow-Derived Mononuclear Cells Promote Improvement in Glomerular Function in Rats with Early Diabetic Nephropathy

Potential role of stem cells for neuropathic pain disorders

Contact Info

Product

Resources

About